KALARIS THERAPEUTICS INC
KLRSNASDAQTrading Snapshot
- Day Range
- $2.89 – $2.96
- 52-Week Range
- $2.91 – $11.88
- Volume
- $1.82B
- Avg Volume
- $1.32B
- Shares Outstanding
- 23.8M
- Next Earnings
- Nov 13, 2026
Fundamentals Snapshot
- Annual Revenue
- $19M
- Last Q Revenue
- $5M
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- $-2.09
- Dividend Yield
- —
- Dilution (1yr)
- +356.2%
Why Investors Own KLRS
- ✓High-growth profile — revenue up +14.3% YoY with expanding US Equity exposure.
- ✓Healthy economics — 53% gross margin and 8% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
KALARIS THERAPEUTICS INC
KLRS
StockOtter · stockotter.spaceAbout KALARIS THERAPEUTICS INC
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), as well as for the treatment of other exudative and neovascular retinal diseases.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Kalaris Therapeutics Inc. (NASDAQ:KLRS) Stock Has Average Price Target of $18.75
Kalaris Therapeutics Inc. (NASDAQ: KLRS - Get Free Report) has been given an average recommendation of "Moderate Buy" by the seven brokerages that are covering the stock, Marketbeat.com reports. One research analyst has
Kalaris to Present at Morgan Stanley 24th Annual Global Healthcare Conference
BERKELEY HEIGHTS, N.J., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments
Kalaris Reports Second Quarter 2026 Financial Results and Provides Business Updates
Patient dosing is ongoing in the Phase 1b/2 study of TH103; preliminary data anticipated in 1H 2027 Potential Phase 3 clinical trials remain on track for initiation by year-end 2027 $93.5 million in cash, cash equivalent
Kalaris Therapeutics (NASDAQ:KLRS) Shares Up 15.4% – Here’s What Happened
Kalaris Therapeutics Inc. (NASDAQ: KLRS - Get Free Report)'s stock price rose 15.4% during mid-day trading on Monday. The company traded as high as $4.09 and last traded at $4.05. Approximately 155,903 shares changed han
KLRS: Abbott Cooper PLLC Announces Investigation on Behalf of Kalaris Therapeutics, Inc. (Formerly Allovir, Inc.) Stockholders
Abbott Cooper PLLC is investigating fiduciary duty claims for Kalaris Therapeutics (formerly AlloVir) holders who owned shares before November 7, 2024.
Kalaris Expands Leadership Team Appointing Liisa Bayko as Chief Financial Officer
Strategic finance leader with over 20+ years of experience in the biotechnology space CFO hire bolsters Kalaris' leadership team and supports continued growth of the company as it enrolls its Phase 1b/2 study of TH103 in